R Seggewiss

Summary

Country: Germany

Publications

  1. ncbi Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update
    R Seggewiss
    Immune Recovery Section, Med Klinik and Poliklinik II, University of Wuerzburg, Wuerzburg, Germany
    Cytotherapy 10:633-41. 2008
  2. ncbi STAT6 and the regulation of CD23 expression in B-chronic lymphocytic leukemia
    C Kneitz
    Medizinische Poliklinik, University of Wurzburg, Klinikstr 6 8, D 97070, Wurzburg, Germany
    Leuk Res 24:331-7. 2000

Collaborators

Detail Information

Publications2

  1. ncbi Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update
    R Seggewiss
    Immune Recovery Section, Med Klinik and Poliklinik II, University of Wuerzburg, Wuerzburg, Germany
    Cytotherapy 10:633-41. 2008
    ..In this brief review, we discuss recent developments in this fast evolving field...
  2. ncbi STAT6 and the regulation of CD23 expression in B-chronic lymphocytic leukemia
    C Kneitz
    Medizinische Poliklinik, University of Wurzburg, Klinikstr 6 8, D 97070, Wurzburg, Germany
    Leuk Res 24:331-7. 2000
    ..It might be involved in the strong induction of CD23 on B-CLL cells after cotreatment with IL-4 and IFN-gamma, while in non-malignant B lymphocytes IFN-gamma leads to a reduction of IL-4 mediated CD23 expression...